- cafead   Jun 03, 2024 at 12:12: PM
via
article source
- $200 Million in Net Proceeds Raised at Premium to Previous Closing Price
- In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to include Latin America, Middle East, and Africa
- Expansion Is in Addition to Existing License Territories of US, Canada, Europe, and Japan
article source